Targeting interleukin-5 with benralizumab: A novel treatment for drug rash with eosinophilia and systemic symptoms

Allergy. 2022 Aug;77(8):2287-2289. doi: 10.1111/all.15283.

Authors

Emanual Maverakis¹, Antonio Ji-Xu¹, Marie-Charlotte Brüggen^{2

3}

Affiliations

¹ Department of Dermatology, University of California, Davis, Sacramento, California, USA.
² Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
³ Christine Kühne Center for Allergy Research and Education CK-CARE, Davos, Switzerland.

PMID: 35285038
DOI: 10.1111/all.15283

No abstract available

Keywords: IL-5; benralizumab; drug rash with eosinophilia and systemic symptoms; mepolizumab; reslizumab.

Publication types

Editorial

MeSH terms

Anti-Asthmatic Agents* / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects
Eosinophilia* / drug therapy
Exanthema* / drug therapy
Humans
Interleukin-5

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Interleukin-5
benralizumab